Conversely, activation of human epithelial growth factor (HER2) homodimers formed in spheroid preparations of breast cancer cells resulted in enhanced inhibition of proliferation in cancer cells treated with trastuzumab (Herceptin), a monoclonal antibody specifically targeting HER2 [28]. This evidence concerns the gene ERBB2 and cancer.